KPF
HZNP

K2 Principal Fund’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

K2 Principal Fund’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-62,500
Closed -$792K – 383
2017
Q3 		$792K Buy
+62,500
New +$795K 0.05% 228

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

K2 Principal Fund's HZNP Position: Q3 2023 in Review

K2 Principal Fund sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 14,500 shares — an estimated $1.49M sold.

K2 Principal Fund first reported a position in HZNP in Q3 2017 and held it in 4 quarters. The position peaked at $2.22M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • K2 Principal Fund reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • K2 Principal Fund sold 14,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $1.49M.
  • K2 Principal Fund first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2017 and held it in 4 quarters.
  • K2 Principal Fund's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.22M in Q1 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on K2 Principal Fund's 13F filing for Q3 2023, filed 13 Nov 2023.